|
Middle Cerebral Artery Occlusion
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BDNF levels decreased progressively after stroke in the MCAo+scrambled group, and this was attenuated in the mir363-3p group.
|
30639697 |
2019 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression levels of MIF and BDNF in the peri-infarct region were upregulated in the MCAO-Ex group.
|
30804254 |
2019 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
Biomarker
|
disease |
BEFREE |
The therapeutic effect of YYTNG may be due to the promotion of neurogenesis in the peri-infarct area and the upregulation of neuroprotective factors BDNF and VEGF in MCAO rats.
|
31006100 |
2019 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
Biomarker
|
disease |
BEFREE |
Enzyme-linked immunosorbent assay (ELISA) analysis of brain, serum and plasma BDNF were performed after the MSC infusion following the MCAO induction.
|
28181779 |
2019 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
Biomarker
|
disease |
BEFREE |
The concentration of brain-derived neurotrophic factor was higher in both hemispheres of MCAO rats with either EGFP/3T3 or EPO/EGFP/3T3 treatment at 14 days poststroke compared with untreated MCAO rats.
|
30920178 |
2019 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The combined therapy increased expression of VEGF and BDNF to a maximum through activating PI3K and ERK1/2 pathways in the hippocampus and frontal cortex in response to transient MCAO.
|
30245466 |
2018 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Berberine also increased the expression of BDNF, TrkB, and p-Akt, which were reduced after MCAO.
|
29357017 |
2018 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We analyzed the effects of 1, 25-D<sub>3</sub> on BBB integrity in terms of histopathological changes, the neurological deficit, infarct size and the expression of brain derived neurotrophic factor (BDNF), in a middle cerebral artery occlusion/reperfusion (MCAO/R) rat model.
|
30618630 |
2018 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results demonstrate that LIPUS effectively prevented the cerebral ischemia/reperfusion injury through apoptosis reduction and BDNF induction in a MCAO mouse model.
|
29615782 |
2018 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
Biomarker
|
disease |
BEFREE |
Male BDNF(+/+) and BDNF(M/M) littermates received sham or transient middle cerebral artery occlusion.
|
24523540 |
2014 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
Biomarker
|
disease |
BEFREE |
In another set of animals, AAV-GFP was co-injected with AAV-BDNF or AAV-RFP to label cells in left SVZ prior to right MCAo.
|
24312581 |
2013 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thus, MSC transfected with the BDNF or GDNF gene resulted in improved function and reduced ischemic damage in a rat model of MCAO.
|
15585410 |
2005 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human mesenchymal stem cells and brain-derived neurotrophic factor-human mesenchymal stem cells were i.v. injected into the rats 6 h after middle cerebral artery occlusion.
|
16229956 |
2005 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rats that received MSC-BDNF showed significantly more functional recovery than did control rats following MCAO.
|
14759803 |
2004 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
Biomarker
|
disease |
BEFREE |
Intracerebral grafting of BDNF-transduced hATSCs significantly improved motor recovery of functional deficits in MCAo rats.
|
14552877 |
2003 |
|
Middle Cerebral Artery Occlusion
|
0.100 |
Biomarker
|
disease |
BEFREE |
High degrees of neuroprotection in transient forebrain ischemia, permanent middle cerebral artery occlusion, or reversible middle cerebral artery occlusion are achieved with the delayed intravenous administration of BDNF chimeric peptides.
|
12575830 |
2002 |